tirzepatide for alcohol use disorder The TRUTH about and The Role of Glucagon-Like Peptide-1

Developed by Eli Lilly, it was approved for marketing in China on May 21st, 2024, and officially launched on January 2nd, 2025

Weight loss drugs such as semaglutide and tirzepatide available under brand names including Ozempic, Wegovy and Mounjaro mimic the naturally-occurring hormone glucagon like peptide-1 (GLP-1), released into the blood in response to eating

840 mg sodium (37% DV)

Unlike single-pathway GLP-1 treatments such as semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide also known as Mounjaro acts on two hormone pathways: GLP-1 and GIP

Understanding who can benefit the most from Ipamorelin and Ibutamoren (MK-677) is key to utilizing these peptides effectively

People who want to manage cravings or emotional eating that could interfere with weight loss efforts